Search

Your search keyword '"Ofer Gemer"' showing total 8 results
Start Over Author "Ofer Gemer" Publisher bmj publishing group ltd
8 results on '"Ofer Gemer"'

1. EPV034/#116 Predicting the rate of adjuvant postoperative chemo/radiation of patients with the recently updated stage IB2 cervical cancer: an Israeli gynecologic oncology group study

Author

Ofer Lavie, Ram Eitan, A. Ben Arie, Tally Levy, I Ben Shachar, Alex Rabinovich, Ilan Bruchim, Zvi Vaknin, A Namazov, S Armon, and Ofer Gemer

Subjects
Oncology, Cervical cancer, medicine.medical_specialty, Group study, business.industry, medicine.medical_treatment, Gynecologic oncology, medicine.disease, Chemo radiation, Internal medicine, medicine, Stage (cooking), business, Adjuvant
Published
2021

2. EPV133/#555 Minimally invasive approach in endometrial cancer with lower uterine segment involvement in ≥ stage ii: is it safe?

Author

Ofer Gemer, A Namazov, Ram Eitan, Amnon Amit, Limor Helpman, T Perri, Zvi Vaknin, Ofer Lavie, I Ben Shachar, Liron Kogan, A. Ben Arie, Tally Levy, Ilan Bruchim, Gabriel Levin, and Ilan Atlas

Subjects
medicine.medical_specialty, Lower uterine segment, business.industry, Endometrial cancer, medicine, Urology, Stage ii, medicine.disease, business
Published
2021

4. EPV136/#605 Metformin use among diabetic women and endometrial cancer survival: an Israeli gynecologic oncology group study

Author

Tally Levy, Ilan Bruchim, Ofer Lavie, Ilan Atlas, Zvi Vaknin, Limor Helpman, Liron Kogan, A. Ben Arie, Ofer Gemer, B Brandt, I Ben Shachar, Ram Eitan, A Namazov, T Perri, and Amnon Amit

Subjects
Oncology, medicine.medical_specialty, Group study, business.industry, Internal medicine, Endometrial cancer, medicine, Gynecologic oncology, medicine.disease, business, Metformin, medicine.drug
Published
2021

5. EPV131/#545 Lower uterine segment involvement in high-grade endometrial carcinoma is not independently associated with adverse oncological outcome

Author

Ofer Lavie, Amnon Amit, Gabriel Levin, Ram Eitan, B Brandt, Tally Levy, Ilan Bruchim, I Ben Shachar, Limor Helpman, A. Ben Arie, Zvi Vaknin, Ilan Atlas, Ofer Gemer, A Namazov, and T Perri

Subjects
medicine.medical_specialty, Lower uterine segment, business.industry, Internal medicine, medicine, Carcinoma, medicine.disease, business, Outcome (game theory), Gastroenterology
Published
2021

6. EPV132/#552 The prognostic impact of lower uterine segment involvement in women with low-risk endometrial carcinoma: a multicenter study

Author

Tally Levy, Ilan Bruchim, Ofer Lavie, Ilan Atlas, Ram Eitan, A Namazov, Gabriel Levin, A. Ben Arie, I Ben Shachar, B Brandt, Ofer Gemer, Zvi Vaknin, Limor Helpman, Amnon Amit, and T Perri

Subjects
medicine.medical_specialty, Lower uterine segment, Multicenter study, business.industry, Internal medicine, medicine, Carcinoma, business, medicine.disease, Gastroenterology
Published
2021

8. 71 The oncological safety of hysteroscopy in the diagnosis of early-stage endometrial cancer: an israel gynecologic oncology group study

Author

Tally Levy, Ilan Bruchim, Ofer Lavie, Ram Eitan, I. Ben Shachar, Amnon Amit, Ilan Atlas, Oded Raban, Zvi Vaknin, Sophia Leytes, Ahmet Namazov, Ofer Gemer, Limor Helpman, Alon Ben-Arie, Michael Volodarsky, and Nasreen Hag-Yahia

Subjects
medicine.medical_specialty, Group study, medicine.diagnostic_test, business.industry, medicine.medical_treatment, Endometrial cancer, Gynecologic oncology, medicine.disease, Curettage, Surgery, Hysteroscopy, Medicine, Stage (cooking), business, Pathological, Endometrial biopsy
Abstract

Objectives To compare survival measures of women with early-stage endometrial cancer who underwent either hysteroscopy or a non-hysteroscopic procedure as a diagnostic procedure. Methods An Israel Gynecologic Oncology Group multicenter study of 1324 patients with stage I endometrial cancer who underwent surgery between 2002 and 2014. Patients were divided into two groups: hysteroscopy and non-hysteroscopy (curettage or office endometrial biopsy). Clinical, pathological, and survival measures were compared between the groups. Results There were 355 patients in the hysteroscopy group and 969 patients in the non-hysteroscopy group. The median follow-up was 52 months (range 12–120 months). There were no differences between the groups in the 5-year recurrence-free survival (90.2% vs. 88.2%; p=0.53), disease-specific survival (93.4% vs. 91.7%; p=0.5), and overall survival (86.2% vs. 80.6%; p=0.22). Conclusions Our findings affirm that hysteroscopy does not compromise the survival of patients with early-stage endometrial cancer.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results